Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients.
BACKGROUND AND AIMS Inflammation and postpr and ial lipemia are associated with increased cardiovascular disease . We investigated whether ezetimibe and simvastatin combination , a lipid lowering combination of simvastatin and ezetimibe , exerts an anti-inflammatory effect in the fasting state and after dairy cream intake . METHODS Twenty obese patients were r and omized to either ezetimibe and simvastatin combination or placebo treatment for 6 weeks . All patients were asked to ingest 33 ml of dairy cream ( 300 Calories ) at the beginning and at the end of intervention . Fasting and post-cream blood sample s were obtained . RESULTS At 0 week , ingestion of cream induced significant increases in MNC expression of IL-1β ( 105 ± 18 % ) , TNFα ( 97 ± 12 % ) , CD68 ( 48 ± 8 % ) , CD16 ( 141 ± 39 % ) , MMP-9 ( 122 ± 31 % ) , PECAM ( 66 ± 10 % ) , TLR-4 ( 84 ± 11 % ) and TLR-2 ( 67 ± 9 % ) and in endotoxin ( LPS ) concentrations ( 49 ± 7 % ) ( p < 0.05 ) . Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol , LDLc and Lp(a ) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1β and CD68 ( by 21 ± 7 and 24 ± 10 , p < 0.05 ) and the concentrations of LPS , CRP , FFA and IL-18 by 24 ± 7 % , 32 ± 11 % , 19 ± 8 % 15 ± 4 % , respectively , ( p < 0.05 ) . Cream-induced increases in the expression of IL-1β , CD68 , CD16 , MMP-9 , TNFα and PECAM were reduced in the ezetimibe and simvastatin combination group by 74 ± 15 % , 68 ± 13 % , 57 ± 13 % , 64 ± 16 % , 67 ± 14 % and 45 ± 9 % , respectively , while those of LPS and MMP-9 concentrations were reduced by 53 ± 9 % and 38 ± 8 % , respectively , compared to the increases at week 0 ( p < 0.05 ) . There was a suppression of TLR-2 and TLR-4 expression by 21 ± 8 % and 18 ± 7 % , respectively , compared to 0-h baseline , after cream intake following ezetimibe and simvastatin combination treatment . CONCLUSIONS Ezetimibe and simvastatin combination exerts a profound anti-inflammatory effect both in the fasting state and acutely after the ingestion of saturated fat
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .